Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia.

The study included only 11 patients, making the results preliminary and anecdotal. The design was retrospective and relied on clinical notes, which may lack comprehensive or accurate details. No objective rating scales were used to measure treatment response. There was no control group, so it is impossible to compare outcomes with general schizophrenia populations. Selection bias is likely, as all participants were referred for existing behavioural or psychiatric problems. The results may not generalize to intellectually disabled individuals without these specific genetic variants or to those without intellectual disability.

The manuscript received no specific grant funding. The author has no direct conflicts of interest for this paper, though he serves as a co-investigator or study physician for trials sponsored by Sunovion, Sumitomo, Otsuka, and Biogen, unrelated to this work.

Do not interpret the response rates as evidence that antipsychotics are universally effective or safe in this population. The sample size was very small, selection bias was high, and side effects including seizures and extrapyramidal symptoms were common.